Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Barclays PLC

Barclays PLC boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 31.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 100,872 shares of the company's stock after purchasing an additional 24,010 shares during the period. Barclays PLC owned about 0.18% of Harmony Biosciences worth $3,471,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Harmony Biosciences by 36.4% during the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock worth $162,883,000 after buying an additional 1,262,362 shares in the last quarter. Norges Bank bought a new position in Harmony Biosciences during the 4th quarter valued at $16,118,000. Pacer Advisors Inc. grew its holdings in Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock worth $78,452,000 after acquiring an additional 351,582 shares in the last quarter. Invesco Ltd. increased its position in shares of Harmony Biosciences by 173.9% in the 4th quarter. Invesco Ltd. now owns 449,180 shares of the company's stock worth $15,456,000 after purchasing an additional 285,156 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Harmony Biosciences by 28.7% in the 4th quarter. American Century Companies Inc. now owns 1,102,604 shares of the company's stock valued at $37,941,000 after purchasing an additional 246,140 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Harmony Biosciences Stock Performance

Shares of HRMY traded up $0.46 during midday trading on Friday, hitting $30.32. 857,912 shares of the stock traded hands, compared to its average volume of 574,483. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61. The business's 50 day moving average price is $31.41 and its two-hundred day moving average price is $34.09. The firm has a market capitalization of $1.74 billion, a PE ratio of 14.37, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. The firm had revenue of $201.30 million during the quarter, compared to analysts' expectations of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 EPS. Equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. UBS Group decreased their price target on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Monday, April 28th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Mizuho upped their price target on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday, March 18th. Needham & Company LLC reiterated a "buy" rating and set a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They set a "buy" rating and a $55.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $52.44.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.